SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. “We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of R ...

BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the best large cap stocks under $100 with huge upside potential. On January 20, Canaccord Genuity analyst Whitney Ijem revised her Hold rating on BioMarin Pharmaceutical (NASDAQ:BMRN) to Buy. She also raised her price target estimate from $84 to $98, offering an upside of almost 75% from the prevailing level. Illumina (ILMN) Jumps 24.8% on Earnings Beat RAJ CREATIONZS / shutterstock.com Ijem’s upward revisions are based on the company’s encouraging fundam ...

Core Insights - Bio-Techne Corporation has launched Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform, enhancing capabilities for neurodegenerative disease research [1][4]. Group 1: Product Launch and Features - The new assays provide step-change improvements in analytical sensitivity and reliable quantification of biomarkers such as NFL, GFAP, pTau 217, and Amyloid (aa1-42) [2][4]. - The Ella platform allows for femtogram-level detection, enabling precise quantification of low-abundance biomarkers that are often undetectable by conventional methods [4][5]. - The automated workflow of Ella reduces manual steps and variability, achieving an overall runtime of under three hours for assay results [4][7]. Group 2: Research Impact and Adoption - The assays facilitate the detection of subtle biological changes, accelerating insights into disease onset, progression, and treatment response [3][4]. - Ella has been cited in over 200 peer-reviewed publications focused on neurology, demonstrating its widespread adoption in translational and clinical research [3][5]. - Bio-Techne's immunoassay leadership is strengthened by combining ultrasensitive assays with automated instrumentation, improving reproducibility and data quality [5]. Group 3: Company Overview - Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people globally [6]. - The company provides innovative tools and bioactive reagents for research and clinical diagnostics, with a broad portfolio that drives breakthroughs in neuroscience research and precision medicine [6][5].

Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday closed around 32% lower after the management update and trial update.Mani Mohindru, a board member since 2021, was named interim CEO, effective immediately. Mark Erlander, CEO, and James Levine, CFO, have stepped down.To maintain financial continuity, Brigitte Lindsay was promoted to Chief Accounting Officer. She has been with the company for more than 14 years and most recently served as Senior Vice President of Finance. Cardiff Oncology has begun a search for ...

Drug developer Eikon Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 million in its U.S. initial public offering, as biotech listings make a comeback. ...

(GAAP)**|**20.40%**||**24.90%**||**12.00%**||**26.80%**||Full year 2025 impact from operating profit margins ofbusinesses that have been owned for less than one yearor were disposed of during such period and did notqualify as discontinued operations|(0.20)||—||(0.30)||(0.15)||Full year 2025 resolution of an acquisition contingency inthe Diagnostics segment|0.05||—||—||0.10||Full year 2025 impairment charges related to tradenames in the Life Sciences and Diagnostics segmentsand technology, other intangible a ...

Core Insights - Mabtech and Sai Life Sciences have formed a strategic collaboration to establish Sai's Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA™ platform [1][2] Group 1: Collaboration Details - The collaboration will jointly deliver advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, utilizing the EYRA platform at Sai's Boston site [2] - This initiative aims to enhance access to next-generation immune profiling capabilities for biopharma and biotech companies involved in immuno-oncology, vaccines, inflammation, and cellular therapy [2][4] Group 2: Platform Features and Benefits - The EYRA platform features intuitive software, automation readiness, and the ability to simultaneously detect dozens of analytes in a single run with minimal hands-on time, addressing limitations of traditional systems [3] - The collaboration allows for the integration of advanced immune profiling into broader discovery and translational strategies, facilitating faster decision-making for discovery clients [4] Group 3: Key Elements of the Collaboration - Key elements include joint service delivery of EYRA-based immunology panels and custom assays, co-branded demonstrations and pilot programs at Sai Boston, shared thought leadership, and integrated business development engagement [7]

Group 1 - The conference call is focused on the data update for Onvansertib, a drug developed by Cardiff Oncology [1] - The call is led by the Interim CEO, Mani Mohindru, along with key members of the Cardiff Oncology team including the Chief Medical Officer and Chief Scientific Officer [2] - The company will be making forward-looking statements regarding guidance, results, and timing of data readouts for Onvansertib clinical studies, which are subject to significant risks and uncertainties [3]

ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the ClearBridge Mid Cap Strategy reported underperformance versus the Russell Midcap Index, which returned 0.16% during the period, as narrow market leadership and sentiment-driven trading weighed on results. Weakness in information technology and real estate holdings pressured returns, while gains in select consumer ...

Core Viewpoint - Sensorion, a clinical-stage biotechnology company focused on hearing loss therapies, announced a €60 million Reserved Offering to specific investors, including Sanofi and existing shareholders, to advance its gene therapy programs [1][2][4]. Funding and Investment - The Reserved Offering involves the issuance of 214,285,714 new ordinary shares at a price of €0.28 per share, with Sanofi investing €20 million and other investors contributing €40 million [1][5]. - The net proceeds from the offering, approximately €56 million, will primarily fund R&D activities for the gene therapy programs SENS-501 and SENS-601 (GJB2-GT) [5][8]. Gene Therapy Programs - SENS-601 (GJB2-GT) is the second gene therapy program entering clinical trials, targeting GJB2 mutations responsible for about 50% of autosomal recessive non-syndromic congenital hearing loss [3][23]. - SENS-501, which targets deafness caused by otoferlin mutations, is already in clinical development [3][23]. Clinical Milestones - Key upcoming clinical milestones include the submission of the Clinical Trial Application for SENS-601 in Q1 2026 and the follow-up data for SENS-501 [6][8]. Shareholder Impact - The issuance of new shares will result in a capital increase of approximately €59.99 million, representing about 71% of the company's share capital before the offering [8][10]. - Existing shareholders who do not participate in the offering will see their ownership diluted; for example, a shareholder with 1% before the offering will hold approximately 0.58% afterward [12][16]. Lock-up Agreements - The company has entered into a lock-up agreement restricting the issuance of additional shares for 90 days following the subscription agreement with investors [17]. Trading and Admission - The new shares will be admitted to trading on Euronext Growth in Paris, expected to occur on January 30, 2026, and will be fungible with existing shares [10][18].